Emerging CRISPR Approaches for Countering Immune Evasion: Insight from Recent Studies
Preprint
- 18 November 2025
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Cancer immunotherapy has recently become an essential approach for treating cancer, showing considerable promise as a substitute for surgery, radiation therapy, and conventional chemotherapy. It primarily aims to boost the host’s natural defense system to com-bat cancer malignancies by utilizing components of immune checkpoint blockades (ICBs), mainly programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), and along with elements of adoptive cellular therapies (ACTs) like Chimeric Antigen Receptor (CAR) therapy, T Cell Receptor (TCR) therapy and Tu-mor-Infiltrating Lymphocyte (TIL) therapy. However, cancer cells tend to undermine the effectiveness of cancer immunotherapeutic strategies by employing one or more immune evasion mechanisms. The present review briefly discusses the key mechanisms of cancer immune evasion and highlights how the CRISPR/Cas9 systems, as gene editing tools, are set to enhance cancer immunotherapy for treating various challenging cancers. We emphasize that CRISPR/Cas9 systems can be used to explore and positively alter the genes of the immune system, boosting the effectiveness of cancer immunotherapy by editing immune checkpoints, TILs, and CAR-T cells, and disrupting genes facilitating tumors to evade the immune system.Keywords
All Related Versions
This publication has 175 references indexed in Scilit:
- CRISPR/Cas9-mediated knockout of DYRK1B in triple-negative breast cancer cells: implications for cell proliferation, apoptosis, and therapeutic sensitivityBiochemical Engineering Journal, 2024
- Optimized lipid nanoparticles enable effective CRISPR/Cas9-mediated gene editing in dendritic cells for enhanced immunotherapyActa Pharmaceutica Sinica B, 2024
- Engineering Cas9: next generation of genomic editorsApplied Microbiology and Biotechnology, 2024
- Current updates of CRISPR/Cas9‐mediated genome editing and targeting within tumor cells: an innovative strategy of cancer managementCancer Communications, 2022
- A Review on the Mechanism and Applications of CRISPR/Cas9/Cas12/Cas13/Cas14 Proteins Utilized for Genome EngineeringMolecular Biotechnology, 2022
- IRF8 regulates efficacy of therapeutic anti‐CD20 monoclonal antibodiesEuropean Journal of Immunology, 2022
- Overview of approved CAR‐T therapies, ongoing clinical trials, and its impact on clinical practiceeJHaem, 2021
- Programmable Unlocking Nano‐Matryoshka‐CRISPR Precisely Reverses Immunosuppression to Unleash Cascade Amplified Adaptive Immune ResponseAdvanced Science, 2021
- Incidence of Programmed Cell Death 1 Inhibitor–Related Pneumonitis in Patients With Advanced CancerJAMA Oncology, 2016
- Nonhomologous DNA End Joining (NHEJ) and Chromosomal Translocations in Humans2009